The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: Time to review the evidence once again

Expert Review of Anticancer Therapy

Volumn 11, Issue 9, 2011, Pages 1367-1378

  Bindra, Ranjit S ^a   Yahalom, Joachim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

diffuse large B cell lymphoma; immunochemotherapy; involved field radiotherapy; non Hodgkin's lymphoma

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CAROTID ARTERY OBSTRUCTION; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; GASTRITIS; HEART DISEASE; HUMAN; HYPOTHYROIDISM; INFECTION; INTERMETHOD COMPARISON; LARGE CELL LYMPHOMA; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIATION DOSE; RADIATION EXPOSURE; REVIEW; SEPSIS; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; XEROSTOMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 80053034903     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.88     Document Type: Review

References (82)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Kaminski MS, Coleman CN, Colby TV, Cox RS, Rosenberg SA. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann. Intern. Med. 104(6), 747-756 (1986). (Pubitemid 16115036)
3. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC. Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br. J. Cancer 69(6), 1088-1093 (1994). (Pubitemid 24161865)
4. Hallahan DE, Farah R, Vokes EE et al. The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone. Int. J. Radiat. Oncol. Biol. Phys. 17(4), 767-771 (1989). (Pubitemid 19250530)
5. Landberg TG, Hakansson LG, Moller TR et al. CVP-remission-maintenance in stage I or II non-Hodgkin's lymphomas: preliminary results of a randomized study. Cancer 44(3), 831-838 (1979). (Pubitemid 10242211)
6. Monfardini S, Banfi A, Bonadonna G et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 6(2), 125-134 (1980). (Pubitemid 10156740)
7. Nissen NI, Ersboll J, Hansen HS et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 52(1), 1-7 (1983). (Pubitemid 13057599)
8. Yahalom J, Varsos G, Fuks Z, Myers J, Clarkson BD, Straus DJ. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 71(7), 2342-2350 (1993). (Pubitemid 23087778)
9. Carde P, Burgers JM, van Glabbeke M et al. Combined radiotherapy- chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial. Radiother. Oncol. 2(4), 301-312 (1984). (Pubitemid 15166540)
10. Longo DL, Glatstein E, Duffey PL et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J. Clin. Oncol. 7(9), 1295-1302 (1989). (Pubitemid 19220132)
11. Shenkier TN, Voss N, Fairey R et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J. Clin. Oncol. 20(1), 197-204 (2002). (Pubitemid 34032612)
12. Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. Ann. Intern. Med. 107(1), 25-30 (1987). (Pubitemid 17098632)
13. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 23(18), 4117-4126 (2005). (Pubitemid 46211317)
14. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 24(19), 3121-3127 (2006). (Pubitemid 46638950)
15. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. J. Clin. Oncol. 7(5), 379-391 (2006).
16. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).J. Clin. Oncol. 9(2), 105-116 (2008).
17. Recher C CB, Haioun C et al. A prospective, randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs. standard R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL).Groupe d'Etude Des Lymphomes De l'Adulte (GELA) study LNH03-2B. Blood (52nd ASH Annual Meeting), Abstract 109 (2010).
18. Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann. Oncol. 13(Suppl. 1), 79-83 (2002). (Pubitemid 34567406)
19. Lee CK. Evolving role of radiation therapy for hematologic malignancies. Hematol. Oncol. Clin. North Am. 20(2), 471-503 (2006). (Pubitemid 43765621)
20. Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N. Engl. J. Med. 339(1), 21-26 (1998). (Pubitemid 28304493)
21. Horning SJ, Weller E, Kim K et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J. Clin. Oncol. 22(15), 3032-3038 (2004). (Pubitemid 41103714)
22. Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 25(7), 787-792 (2007). (Pubitemid 350002878)
23. Reyes F, Lepage E, Ganem G et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N. Engl. J. Med. 352(12), 1197-1205 (2005). (Pubitemid 40397261)
24. Ballonoff A, Rusthoven KE, Schwer A et al. Outcomes and effect of radiotherapy in patients with stage I or II diffuse large B-cell lymphoma: a surveillance, epidemiology, and end results analysis. Int. J. Radiat. Oncol. Biol. Phys. 72(5), 1465-1471 (2008).
25. Phan J, Mazloom A, Jeffrey Medeiros L et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J. Clin. Oncol. 28(27), 4170-4176 (2010).
26. Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N. Engl. J. Med. 356(23), 2399-2405 (2007).
27. Powell ME. Modern radiotherapy and cervical cancer. Int J Gynecol Cancer, 20(11 Suppl. 2), S49-S51 (2010).
28. Alvarez Secord A, Havrilesky LJ, Bae-Jump V et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol. Oncol. 107(2), 285-291 (2007). (Pubitemid 47575727)
29. Duenas-Gonzalez A, Cetina L, Mariscal I, de la Garza J. Modern management of locally advanced cervical carcinoma. Cancer Treat. Rev. 29(5), 389-399 (2003). (Pubitemid 37185105)
30. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. Semin. Radiat. Oncol. 20(1), 58-66 (2010).
31. Wolden SL, Alektiar KM. Sarcomas across the age spectrum. Semin. Radiat. Oncol. 20(1), 45-51 (2010).
32. Yahalom J. Does radiotherapy still have a place in Hodgkin lymphoma? Curr. Hematol. Malig. Rep. 4(3), 117-124 (2009).
33. Straus DJ. The case for chemotherapy only for localized Hodgkin lymphoma. Oncologist 14(12), 1225-1231 (2009).
34. Klimm B, Engert A. Combined modality treatment of Hodgkin's lymphoma. Cancer J. 15(2), 143-149 (2009).
35. Herbst C, Engert A. Meta-analyses of early-stage hodgkin lymphoma. Acta Haematol 125(1-2), 32-38 (2011).
36. Eich HT, Diehl V, Gorgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J. Clin. Oncol. 28(27), 4199-4206 (2010).
37. Engert A, Plutschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N. Engl. J. Med. 363(7), 640-652 (2010).
38. Herbst C, Rehan FA, Brillant C et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 95(3), 494-500 (2010).
39. Engert A, Eichenauer DA, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v168-v171 (2010).
40. Miller TP, LeBlanc M, Spier CM. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphoma: update of the Southwest Oncology Groups (SWOG) randomized trial. Blood 98(98), 724a (2001).
41. No authors listed. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 329(14), 987-994 (1993).
42. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 26(19), 3159-3165 (2008).
43. Moser EC, Noordijk EM, van Leeuwen FE et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107(7), 2912-2919 (2006).
44. Pugh TJ, Ballonoff A, Rusthoven KE et al. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis. Int. J. Radiat. Oncol. Biol. Phys. 76(3), 845-849 (2010).
45. Smith LA, Cornelius VR, Plummer CJ et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10, 337 (2010).
46. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat. Rep. 62(6), 873-879 (1978). (Pubitemid 8377881)
47. Carver JR, Shapiro CL, Ng A et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. 25(25), 3991-4008 (2007). (Pubitemid 47477279)
48. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91(5), 710-717 (1979). (Pubitemid 10218041)
49. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102(13), 4284-4289 (2003). (Pubitemid 37494085)
50. Tilly H, Mounier N, Lederlin P et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. J. Clin. Oncol. 18(6), 1309-1315 (2000). (Pubitemid 30159850)
51. Andre M, Mounier N, Leleu X et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 103(4), 1222-1228 (2004). (Pubitemid 38168631)
52. Fillet G, Bonnet C. In Reply. J. Clin. Oncol. 25(19), 2857-2858 (2007).
53. Tsoutsou PG, Belkacemi Y, Gligorov J et al. Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. Oncologist 15(11), 1169-1178 (2010).
54. Wyatt RM, Jones BJ, Dale RG. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br. J. Radiol. 81(967), 549-563 (2008). (Pubitemid 351957741)
55. Persky DO, Unger JM, Spier CM et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J. Clin. Oncol. 26(14), 2258-2263 (2008).
56. Morschhauser F, Illidge T, Huglo D et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110(1), 54-58 (2007). (Pubitemid 47026818)
57. Zinzani PL, Rossi G, Franceschetti S et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin. Cancer Res. 16(15), 3998-4004 (2010).
58. Zinzani PL, Tani M, Fanti S et al. A Phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann. Oncol. 19(4), 769-773 (2008). (Pubitemid 351461050)
59. Miller TP, Unger JM, Spier CM. Effect of adding ibritumomab tiuxetan (zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG 0313).Blood 112(11), (2008) (Abstract 3598).
60. Swerdlow AJ, Schoemaker MJ, Allerton R et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J. Clin. Oncol. 19(6), 1610-1618 (2001). (Pubitemid 32230860)
61. Hill DA, Gilbert E, Dores GM et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 106(10), 3358-3365 (2005). (Pubitemid 41609165)
62. Travis LB, Hill DA, Dores GM et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290(4), 465-475 (2003). (Pubitemid 37430500)
63. Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J. Natl Cancer Inst. 94(3), 182-192 (2002). (Pubitemid 34162752)
64. Brennan P, Scelo G, Hemminki K et al. Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma. Br. J. Cancer 93(1), 159-166 (2005). (Pubitemid 41078800)
65. Lavey RS, Eby NL, Prosnitz LR. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 66(1), 80-88 (1990). (Pubitemid 20197089)
66. Mudie NY, Swerdlow AJ, Higgins CD et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J. Clin. Oncol. 24(10), 1568-1574 (2006). (Pubitemid 46638780)
67. Sacchi S, Marcheselli L, Bari A et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. Haematologica 93(9), 1335-1342 (2008).
68. Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann. Oncol. 22(8), 1845-1858 (2011).
69. Morton LM, Curtis RE, Linet MS et al. Second malignancy risks after non- Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J. Clin. Oncol. 28(33), 4935-4944 (2010).
70. Moser EC, Noordijk EM, van Leeuwen FE et al. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica 91(11), 1481-1488 (2006). (Pubitemid 44736114)
71. Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin's disease. N. Engl. J. Med. 322(1), 7-13 (1990).
72. Kaldor JM, Day NE, Pettersson F et al. Leukemia following chemotherapy for ovarian cancer. N. Engl. J. Med. 322(1), 1-6 (1990). (Pubitemid 20023825)
73. Haas JF, Kittelmann B, Mehnert WH et al. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br. J. Cancer 55(2), 213-218 (1987). (Pubitemid 17021686)
74. Gomez GA, Aggarwal KK, Han T. Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non- Hodgkin's lymphoma. Cancer 50(11), 2285-2288 (1982). (Pubitemid 13244161)
75. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J. Clin. Oncol. 21(5), 897-906 (2003). (Pubitemid 46613489)
76. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107(1), 108-115 (2006). (Pubitemid 43939037)
77. Travis LB, Weeks J, Curtis RE et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J. Clin. Oncol. 14(2), 565-571 (1996). (Pubitemid 26051022)
78. Friedman DL, Kadan-Lottick NS, Whitton J et al. Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 14(8), 1922-1927 (2005). (Pubitemid 41161201)
79. Hoskin PJ, Falk S et al. Radiation dose in non-Hodgkin's lymphoma: preliminary results of a UK NCRN randomised trial. Ann. Oncol. (2005).
80. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000). (Pubitemid 30082188)
81. Ninan MJ, Wadhwa PD, Gupta P. Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leuk. Lymphoma 52(3), 360-373 (2011).
82. Sehn SK, Hoskins P et al. Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone. Ann. Oncol. 19(Suppl. 4), Abstract 052 (2008).